rosiglitazone Articles
Avandia to be tested in diabetes prevention
9 November 2000
Modernizing Merck KGaA looking to long-term growth from pharma
8 November 2000
FDA concerns over SB's Avandia materials
2 November 2000
Strong earnings growth for Glaxo Wellcome and SmithKline Beecham
1 November 2000
B-MS gets OK for Glucophage XR
18 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
NICE verdict on SB's Avandia positive
18 August 2000
B-MS gains FDA OK for Glucovance
4 August 2000
SB launches diabetes drug Avandia in UK
25 July 2000
SB gains approval for Avandia in EU
18 July 2000
Indian firm files EMR on SB's rosiglitazone
14 July 2000
Takeda gets CPMP backing for Actos
7 July 2000
ADA meeting - SB to study Avandia in long-term trial
14 June 2000
Glaxo SmithKline merger "makes cents"
5 June 2000
Stock Commentary Europe
25 May 2000
Takeda benefits from strong US showing
24 May 2000
Stock Commentary Tokyo
27 April 2000
SB tops UK corporate reputation list in March
25 April 2000
Lilly and Ono link up for sivelestat critical care drug
18 April 2000
Stock Commentary Tokyo
13 April 2000
Actos takes the lead in new prescriptions
13 April 2000
NICE dismisses taxane clearance speculation
12 April 2000
Stock Commentary Tokyo
3 April 2000
Stock Commentary Europe
23 March 2000
Stock Commentary Tokyo
23 March 2000
SB wins Avandia approval in Europe, but use restricted
17 March 2000
Avandia implicated again in hepatic injury, SB denies link
19 January 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
SB's Avandia "leading the class" in the USA
13 January 2000
Synthon challenges SB's Paxil patent?
10 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Takeda to launch Actos in Japan; $1bn drug?
2 December 1999
Merck KGaA's strong results suggests big not necessarily beautiful
19 November 1999
SB unveils new trial of Avandia
5 November 1999
Stock Commentary Europe
4 November 1999
SB Avandia concerns "not related to liver toxicity"
28 October 1999
Stock Commentary Europe
28 October 1999
Avandia CPMP knockback overshadows SB's promising growth
25 October 1999
Stock Commentary Europe
11 October 1999
SB rebuffs suggestion of Avandia toxicity
11 October 1999
Stock Commentary Tokyo
30 September 1999
Stock Commentary Europe
16 September 1999
Stock Commentary Europe
9 September 1999
FDA has no plans for warning label on SB's diabetes drug
8 September 1999
SB denies Avandia liver damage rumors
2 September 1999
Stock Commentary Europe
2 September 1999
Stock Commentary Europe
5 August 1999
Stock Commentary Tokyo
29 July 1999
SB sales increase 11% boosted by Avandia
21 July 1999
Actos approval shortly?
16 July 1999
SB in India hopes to double exports
9 July 1999
Beyond Prozac : Lilly outlines future
14 June 1999
Stock Commentary Tokyo
3 June 1999
Stock Commentary Europe
3 June 1999
Stock Commentary Tokyo
27 May 1999
Strong net profits growth for Sankyo
24 May 1999
Novo Nordisk posts solid first-quarter sales
13 May 1999
Stock Commentary Europe
6 May 1999
Stock Commentary New York
29 April 1999
Stock Commentary Europe
29 April 1999
SB boosted as Avandia is backed by FDA advisory panel
23 April 1999
Stock Commentary Europe
22 April 1999
SB drops development of idoxifene in osteoporosis
21 April 1999
UK drug stock's rebound sustainable, says Commerzbank
13 April 1999
Priority review for Takeda's Actos in USA
18 March 1999
Stock Commentary Tokyo
4 March 1999
Future growth of the global pharmaceutical market evaluated by MSDW
23 February 1999
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
